Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Ophthalmology
Eye Disorders/Infections
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
Does your child suffer from lid and eye irritation?
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
Research study for children and adults with symptoms of
pink eye
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
Dry Eye Disease-Adults
Eye infection: Itchy eyelid, foreign body sensation, ocular dryness, burning or pain, and swollen or heavy eyelids?
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
Have you been diagnosed with dry age-related macular degeneration (AMD)?
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
The OCTAGON clinical study is a multicenter, randomized, placebo controlled clinical research study designed to explore the effects of the drug glatiramer acetate on visual function in people with acute optic neuritis (AON) vs. placebo. Glatiramer acetate is currently being used in the treatment of relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to determine if glatiramer acetate is effective, safe, and tolerable in reducing the amount of axonal loss or retinal nerve fiber layer loss in the eye after a first event of AON.
